Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in B-Cell Lymphoid Malignancies
NCT02343120Phase 2Completed
- Sponsor
- BeiGene
- Start
- Sep 2014
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in B-cell lymphoid malignancy, sponsored by BeiGene. Primary endpoints: Number of Participants With Adverse Events and Recommended Phase 2 Dose (RP2D) for Zanubrutinib at Month 9. Started Sep 2014; status: completed.
02
Drugs
zanubrutinib
03
Conditions
B-cell lymphoid malignancy
Beyond the preview
Go deeper on NCT02343120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343120.